This study was conducted to determine if the behavioral asymmetry associated with unilateral nigrostriatal dopamine (DA) depletion could be alleviated by placing a small DA-releasing silicone polymer matrix pellet into the denervated striatum of rats. Animals that received DA-releasing pellets showed a 50% reduction in apomorphine-induced rotational behavior, and this effect persisted for the 2-month duration of the experiment. The results suggest that the controlled release of DA from an intrastriatal polymer matrix can produce a long-lasting reduction in some of the symptons associated with DA depletion.
INTRODUCTION
Rats with a large unilateral lesion of the nigrostriatal dopamine (DA) system show behavioral asymmetries similar to those seen in people with hemi-Parkinsonism, and these behavioral asymmetries are accentuated by treatment with DA agonists 18'19. For example, the directacting DA receptor agonist, apomorphine (APO), causes animals to turn in circles contralateral to the lesion side due to the action of APO at supersensitive DA receptors in the denervated striatum 4'18'19. Grafts of DA-containing tissue (either fetal substantia nigra or adrenal medulla tissue) in or near the denervated striatum reduce the DA receptor supersensitivity, an effect that is manifest as a decrease in APO-induced turning behavior 6"7'9-11'14.
The mechanism through which tissue grafts induce their behavioral effect is still unknown. One possibility is that tissue grafts alleviate the behavioral asymmetry produced by unilateral DA depletion by simply providing a supplementary source of DA. If this is the case, it may be possible to produce a similar restoration of function by providing the striatum with DA through alternative means.
The present experiment was designed as a preliminary test of this hypothesis. DA was provided via a small DA-silicone polymer pellet that slowly and continuously released DA. It is reported that placement of a DAreleasing pellet into the denervated striatum of rats with a unilateral nigrostriatal DA lesion reduced APO-evoked rotational behavior by 50% for the 2-month duration of the experiment.
MATERIALS AND METHODS

Intrastriatal DA-silicone matrix implants
The DA-silicone matrix was prepared by mixing 20 parts of DA hydrochloride in 80 parts of polymethyisiloxane monomer (Silastic 382, Dow Corning, Midland, MI) with stannous octanoate as catalyst, using procedures similar to those previously describedlZ.The mixture was molded into strips 1 cm wide and 1 mm thick and cured at room temperature. Control implant material was prepared in the same way, but did not contain DA. Pellets for implantation were made by punching 1-mm diameter pieces from the polymer strip with a stainless-steel punch, and then incubating the pellets for 18-24 h in 0.9% saline at 37 °C. Individual pellets weighed 0.64 + 0.05 mg prior to incubation. Some pellets were placed into the striatum in one piece, and others were cut in half and placed at two sites within the striatum, as described below.
DA release from silicone matrix implants
In vitro experiments were conducted to estimate the rate of DA release from the silicone polymer matrix. Pellets of DA-containing polymer 1 mm diameter (n = 5) were incubated in 0.05 M potassium phosphate buffer with 10 mM Na2S205, pH 7.4 at 37 °C. Incubation was conducted in 1.5 ml plastic-capped tubes. When these tubes were completely filled with buffer and tightly capped, no DA oxidation was observed. The incubation solutions were changed at: 1, 2, 3, 6, 7, 10, 14, 21, 28, 35, 42 and 56 days; The solubilized DA released from the pellets was monitored by HPLC-EC as previously described ~6 and the rate of DA release from the matrix was determined over the 7-week time period. In separate experiments, 1 cm 2 pieces (n = 4) were incubated in 9 ml buffer. DA release from the matrix in these experiments was quantified by absorbance at 279 nm at 1, 2, 3, 6 and 24 h and at 2, 3, 6, 7, 10, 14, 21, 35 and 42 days of incubation.
Subjects and experimental procedures
Male Holtzman rats (Madison, WI; n = 23) weighing 20(l-250 g received a unilateral 6-hydroxydopamine lesion of the substantia nigra, as previously described ~~('. Beginning 2 weeks after the lesion all animals were tested for baseline rates of APO-induced rotational behavior (0.25 mg/kg, s.c.) in automated rotometers ~5, Each rat was tested 2-3 times, with 3 days between tests. Only rats that made more than 90 full rotations (360 ° turns) during at least two of the 40-min test sessions were included in the study. Animals that meet this criteria invariably have a >90% striatal DA depletion.
Ten days after the last baseline test each animal was anesthetized with sodium pentobarbital supplemented with methoxyflurane. Using standard stereotaxic techniques and aseptic surgical procedures, one or two small pellets of the silicone-polymer matrix were placed into the denervated striatum of each animal using a trocar device constructed in the laboratory (coordinates (from Bregma, with Bregma and Lambda horizontal), single pellet: AP +0.5 mm. At the completion of the behavioral experiment the animals were perfused with 0.9% saline followed by 10% formalin. The brains were removed and stored in 1()~; formalin until frozen sections (4(I ,~m thick) were obtained. The location of the pellets within the brain was determined by examination of Cresyl violet-stained sections. Four animals were excluded because their pellets were not in the intended location.
RESULTS
The rate of DA release from the silicone matrix in vitro was not dramatically influenced by the shape/size of the matrix. As can be seen in Fig. 1 , with both configurations of the matrix there is a very rapid release of DA during the first 24 h in vitro. The DA-silicone polymer matrix pellets used in the behavioral experiments released approximately 373.6 + 20.0 nmol DA/ pellet (mean _+ S.E.M.) or about 55% of the DA contained in the pellet during this period prior to implantation. Between days 1 and 10 in vitro, the pellets released an additonal 37% of the total DA. Between days 10 and 60, DA release continued to decrease. A total of 1.69 + 0.13 nmol DA/pellet or 2.5% was released during this period of time in vitro. Release of DA from the larger pieces of DA-silicone matrix was slightly less during the initial dynamic phase of DA release, but the profile of the time course is quite similar (Fig. 1) . It must be stressed, however, that how well release rate in vitro approximates release in vivo is not known.
Both control and experimental animals showed a marked, but transient, reduction in APO-induced turning behavior 1-3 days after implantation of the polymer pellets. The reduction was significantly greater, however, in animals with DA-releasing pellets. On day 3 postoperatively, turning in control animals was 77.3 + 9.5% (mean +_ S.E,M.) of baseline, whereas experimental animals turned at a rate that was only 32.0 _+ 8.1% of baseline (baseline = 100%). By 10 days postoperatively the rate of turning had stabilized in both experimental and control animals, but rats with DA-releasing pellets showed a greater reduction in turning behavior than did control animals for the remainder of the experiment (P < 0.002). Animals with Fig. 3 . Correlation between the distance from the ventricle of DA-releasing silicone polymer implants and the percent reduction in rotational behavior. Each data point represents one individual animal. Pellets placed close to the ventricle within the striatum were most effective in producing a reduction in APO-induced rotational behavior. Fig. 4 . Cresyl violet-stained section (40 pm tick) of striatum adjacent to the site of a DA-silicone polymer pellet (initial negative enlargement x 50). * Indicates the site where the pellet was found in the striatum. Note the thin layer of fibrous appearing material and gliosis immediately adjacent to the cavity formed by the pellet, but the normal appearance of the striatal neurons within a few microns of the implant site.
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DA-silicone pellets turned at a rate that was less than 50% of baseline when animals were tested at 30 and 60 days after implantation (Fig. 2) . In contrast, between 10 and 60 days postoperatively the rate of turning in control animals was not significantly different from baseline.
Interestingly, the location of the pellet within the striatum was a significant factor in how effectively the implant reduced rotational behavior (Fig. 3) . The more lateral the placement the smaller the decrease in rotational behavior (r = 0.693, P = 0.001). This finding is similar to that described by Dunnett and colleagues using fetal substantia nigra grafts transplanted into striatum 7~. It should also be noted that in two animals the pellet was inadvertently positioned within the ventricle and in these animals rotational behavior was not reduced (data not shown).
Examination of the histology showed that there were no gross tissue compatibility problems with this polymer matrix. There was a thin layer of fibrous tissue and gliosis immediately adjacent to the site of implant, but normal appearing neurons within a few microns of the implant cavity (Fig. 4) . This was expected because the silicone polymer has received FDA approval for biomedical applications. Similar tissue compatibility has been recently reported following implantation of polyvinyt acrylic copolymer capsules into neocortex 1"2°.
DISCUSSION
Implantation of a silicone polymer pellet that released DA into the denervated striatum reduced the behavioral asymmetry associated with unilateral nigrostriatal DA depletion. While a transient reduction in rotational behavior was observed in control animals (probably due to non-specific trauma associated with the surgery) turning rates had returned to preimplant levels by day 10. In contrast, animals with DA-releasing implants showed a significantly greater decrease in turning at 3 days postimplant, than did animals with control implants, and continued to exhibit reduced rotational behavior for 2 months. Exactly how long the pellets would continue to be effective in vivo remains to be determined,
The magnitude of the decrease in the APO-stimulated rotational behavior seen here is comparable to that obtained with other procedures. For example, a 25-50% reduction in APO-induced rotation is seen with adrenal medulla grafts 9"]1'17, or with the intrastriatal infusion of DA (0.5-5 /*g/h) using an osmotic mini-pump for two weeks (ref. 13; see also ref. 17) . In the present study, in vitro release from the pellets decreased from 385 to 16 pg/h (or from 150.8 to 6.3 fmol/min) between days 10 and 56. Whereas this rate of DA release is very low, it is within the range of normal extracellular DA-release rates reported in microdialysis studies 16 and the behavioral evidence indicates that release was sufficient to maintain suppression of rotational behavior by 50%. It is also relevant that DA diffuses quite freely through a DAdepleted striatum, unlike the intact striatum where diffusion is prevented by re-uptake into presynaptic DA terminals 5. It should be noted, that the rate of DA release during this time period was declining gradually and that in vitro experiments at best provide only a rough estimate of release rate in vivo. However, previous work by others has demonstrated that there is a close correspondence between in vitro and in vivo drug release with some polymer matrix systems ~. Nevertheless, further experiments will be required to determine the in vivo rate of DA release from the type of silicone polymer pellets used here.
Although the magnitude of the reduction in APOinduced rotational behavior seen here was close to that seen with adrenal medulla grafts it is not known whether this represents the maximal effect possible using this procedure. It may be, for example, that the silicone polymer pellets were not optimally placed in the striatum for reducing rotational behavior, or that the dose was suboptimal. Whether other sites within the striatum may be more effective is currently under investigation, as are dose-response studies.
In conclusion, this preliminary study demonstrates that it is possible to produce a sustained reduction in the symptoms associated with striatal DA depletion by chronic implantation of an exogenous source of DA, such as the controlled release DA-silicone polymer matrix pellet used here. This supports the idea that in some neural systems grafts may only need to provide a tonic, unregulated source of neurotransmitter to be effective; i.e. integration of the graft and host is not necessary 2. Of course, many more experiments will be required to thoroughly evaluate the technique described here. For example, additional experiments will be required to determine the extent and rate of DA diffusion in vivo as well as the long-term stability of DA within the silicone polymer matrix. In addition, the polymer used was not ideal because release was continuously decreasing over time. Polymers from which release occurs at a constant rate (i.e. zero-order release kinetics) may be more beneficial. We are currently experimenting with the use of rate-limiting membranes ~2 to achieve zero-order release kinetics from polymer matrices of this type. Even more important to possible clinical applications, the ability of DA-releasing pellets to alleviate other behavioral symptoms of striatal DA depletion must be thoroughly evaluated (especially following bilateral insult). Nevertheless, the experiment reported here suggests this approach could potentially provide an alternative to tissue grafts in the treatment of Parkinson's Disease.
